tiprankstipranks
Neurocrine (NBIX)
NASDAQ:NBIX
US Market
NBIX
Neurocrine
RESEARCH TOOLSreports
Want to see NBIX full AI Analyst Report?

Neurocrine (NBIX) Stock Forecast & Price Target

1,568 Followers
See the Price Targets and Ratings of:

NBIX Analyst Ratings

Strong Buy
23Ratings
Strong Buy
21 Buy
2 Hold
0 Sell
Based on 23 analysts giving stock ratings to
Neurocrine
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

NBIX Stock 12 Month Forecast

Average Price Target

$182.79
▲(37.18% Upside)
Based on 23 Wall Street analysts offering 12 month price targets for Neurocrine in the last 3 months. The average price target is $182.79 with a high forecast of $242.00 and a low forecast of $140.00. The average price target represents a 37.18% change from the last price of $133.25.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"105":"$105","174":"$174","243":"$243","139.5":"$139.5","208.5":"$208.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":242,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$242.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":182.78947368421052,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$182.79</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":140,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$140.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[105,139.5,174,208.5,243],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,132.56,140.97846153846154,149.3969230769231,157.81538461538463,166.23384615384617,174.65230769230772,183.07076923076923,191.48923076923077,199.90769230769232,208.32615384615386,216.7446153846154,225.16307692307691,233.58153846153846,{"y":242,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,132.56,136.4238056680162,140.2876113360324,144.1514170040486,148.01522267206477,151.87902834008096,155.74283400809716,159.60663967611336,163.47044534412956,167.33425101214573,171.19805668016193,175.06186234817812,178.92566801619432,{"y":182.78947368421052,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,132.56,133.1323076923077,133.70461538461538,134.27692307692308,134.84923076923076,135.42153846153846,135.99384615384616,136.56615384615384,137.13846153846154,137.71076923076924,138.28307692307692,138.85538461538462,139.4276923076923,{"y":140,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":107,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.59,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":124.56,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128.91,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":141.92,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":143.21,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":150.88,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":141.83,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137.63,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.38,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.56,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$242.00Average Price Target$182.79Lowest Price Target$140.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Needham Analyst forecast on NBIX
Ami Fadia
Needham
Needham
―
Buy
―
Reiterated
04/24/26
Needham Sticks to Its Buy Rating for Neurocrine (NBIX)
Morgan Stanley Analyst forecast on NBIX
Sean Laaman
Morgan Stanley
Morgan Stanley
$185
Hold
38.84%
Upside
Reiterated
04/20/26
Neurocrine Biosciences: Conservative VYKAT XR Outlook and Aggressive Margin Assumptions Justify Hold Rating
Bank of America Securities Analyst forecast on NBIX
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
04/15/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Galmed Pharmaceuticals (NASDAQ: GLMD), Neurocrine (NASDAQ: NBIX) and Mesoblast (NASDAQ: MESO)
H.C. Wainwright Analyst forecast on NBIX
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$192→$215
Buy
61.35%
Upside
Reiterated
04/07/26
Neurocrine price target raised to $215 from $192 at H.C. WainwrightNeurocrine price target raised to $215 from $192 at H.C. Wainwright
Wedbush Analyst forecast on NBIX
Laura Chico
Wedbush
Wedbush
$151→$166
Buy
24.58%
Upside
Reiterated
04/07/26
Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX) and Centene (NYSE: CNC)
Jefferies Analyst forecast on NBIX
Akash Tewari
Jefferies
Jefferies
$172
Buy
29.08%
Upside
Reiterated
04/07/26
Jefferies Reaffirms Their Buy Rating on Neurocrine (NBIX)
Truist Financial Analyst forecast on NBIX
Danielle Brill
Truist Financial
Truist Financial
―
Buy
―
Reiterated
04/07/26
Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX), Bausch + Lomb Corporation (NYSE: BLCO) and UnitedHealth (NYSE: UNH)
RBC Capital Analyst forecast on NBIX
Brian Abrahams
RBC Capital
RBC Capital
$177→$176
Buy
32.08%
Upside
Reiterated
04/07/26
Neurocrine price target lowered to $176 from $177 at RBC CapitalNeurocrine price target lowered to $176 from $177 at RBC Capital
Canaccord Genuity Analyst forecast on NBIX
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
$164→$200
Buy
50.09%
Upside
Reiterated
04/07/26
Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX), Guardant Health (NASDAQ: GH) and Compass Therapeutics (NASDAQ: CMPX)
William Blair Analyst forecast on NBIX
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
04/06/26
Analysts Conflicted on These Healthcare Names: Oncolytics Biotech (NASDAQ: ONCY) and Neurocrine (NASDAQ: NBIX)
Wolfe Research Analyst forecast on NBIX
Rudy Li
Wolfe Research
Wolfe Research
$160
Buy
20.08%
Upside
Reiterated
04/06/26
Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX) and Theravance Biopharma (NASDAQ: TBPH)
BMO Capital Analyst forecast on NBIX
Evan Seigerman
BMO Capital
BMO Capital
$131.6→$140
Hold
5.07%
Upside
Assigned
04/06/26
Balanced View on Neurocrine Biosciences: Favorable Soleno Acquisition Prospects Offset by Long-Term Ingrezza and Orphan Market Execution Risks
Citi Analyst forecast on NBIX
Yigal Nochomovitz
Citi
Citi
$204→$242
Buy
81.61%
Upside
Assigned
04/06/26
Neurocrine price target raised to $242 from $204 at CitiNeurocrine price target raised to $242 from $204 at Citi
UBS Analyst forecast on NBIX
Ashwani Verma
UBS
UBS
$161
Buy
20.83%
Upside
Reiterated
04/06/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
J.P. Morgan Analyst forecast on NBIX
Anupam Rama
J.P. Morgan
J.P. Morgan
$176→$177
Buy
32.83%
Upside
Assigned
03/12/26
Neurocrine price target raised to $177 from $176 at JPMorganNeurocrine price target raised to $177 from $176 at JPMorgan
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Needham Analyst forecast on NBIX
Ami Fadia
Needham
Needham
―
Buy
―
Reiterated
04/24/26
Needham Sticks to Its Buy Rating for Neurocrine (NBIX)
Morgan Stanley Analyst forecast on NBIX
Sean Laaman
Morgan Stanley
Morgan Stanley
$185
Hold
38.84%
Upside
Reiterated
04/20/26
Neurocrine Biosciences: Conservative VYKAT XR Outlook and Aggressive Margin Assumptions Justify Hold Rating
Bank of America Securities Analyst forecast on NBIX
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
04/15/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Galmed Pharmaceuticals (NASDAQ: GLMD), Neurocrine (NASDAQ: NBIX) and Mesoblast (NASDAQ: MESO)
H.C. Wainwright Analyst forecast on NBIX
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$192→$215
Buy
61.35%
Upside
Reiterated
04/07/26
Neurocrine price target raised to $215 from $192 at H.C. WainwrightNeurocrine price target raised to $215 from $192 at H.C. Wainwright
Wedbush Analyst forecast on NBIX
Laura Chico
Wedbush
Wedbush
$151→$166
Buy
24.58%
Upside
Reiterated
04/07/26
Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX) and Centene (NYSE: CNC)
Jefferies Analyst forecast on NBIX
Akash Tewari
Jefferies
Jefferies
$172
Buy
29.08%
Upside
Reiterated
04/07/26
Jefferies Reaffirms Their Buy Rating on Neurocrine (NBIX)
Truist Financial Analyst forecast on NBIX
Danielle Brill
Truist Financial
Truist Financial
―
Buy
―
Reiterated
04/07/26
Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX), Bausch + Lomb Corporation (NYSE: BLCO) and UnitedHealth (NYSE: UNH)
RBC Capital Analyst forecast on NBIX
Brian Abrahams
RBC Capital
RBC Capital
$177→$176
Buy
32.08%
Upside
Reiterated
04/07/26
Neurocrine price target lowered to $176 from $177 at RBC CapitalNeurocrine price target lowered to $176 from $177 at RBC Capital
Canaccord Genuity Analyst forecast on NBIX
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
$164→$200
Buy
50.09%
Upside
Reiterated
04/07/26
Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX), Guardant Health (NASDAQ: GH) and Compass Therapeutics (NASDAQ: CMPX)
William Blair Analyst forecast on NBIX
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
04/06/26
Analysts Conflicted on These Healthcare Names: Oncolytics Biotech (NASDAQ: ONCY) and Neurocrine (NASDAQ: NBIX)
Wolfe Research Analyst forecast on NBIX
Rudy Li
Wolfe Research
Wolfe Research
$160
Buy
20.08%
Upside
Reiterated
04/06/26
Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX) and Theravance Biopharma (NASDAQ: TBPH)
BMO Capital Analyst forecast on NBIX
Evan Seigerman
BMO Capital
BMO Capital
$131.6→$140
Hold
5.07%
Upside
Assigned
04/06/26
Balanced View on Neurocrine Biosciences: Favorable Soleno Acquisition Prospects Offset by Long-Term Ingrezza and Orphan Market Execution Risks
Citi Analyst forecast on NBIX
Yigal Nochomovitz
Citi
Citi
$204→$242
Buy
81.61%
Upside
Assigned
04/06/26
Neurocrine price target raised to $242 from $204 at CitiNeurocrine price target raised to $242 from $204 at Citi
UBS Analyst forecast on NBIX
Ashwani Verma
UBS
UBS
$161
Buy
20.83%
Upside
Reiterated
04/06/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
J.P. Morgan Analyst forecast on NBIX
Anupam Rama
J.P. Morgan
J.P. Morgan
$176→$177
Buy
32.83%
Upside
Assigned
03/12/26
Neurocrine price target raised to $177 from $176 at JPMorganNeurocrine price target raised to $177 from $176 at JPMorgan
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Neurocrine

3 Months
xxx
Success Rate
16/25 ratings generated profit
64%
Average Return
+3.12%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 64.00% of your transactions generating a profit, with an average return of +3.12% per trade.
1 Year
Phil NadeauTD Cowen
Success Rate
13/22 ratings generated profit
59%
Average Return
+5.30%
Copying Phil Nadeau's trades and holding each position for 1 Year would result in 59.09% of your transactions generating a profit, with an average return of +5.30% per trade.
2 Years
xxx
Success Rate
19/28 ratings generated profit
68%
Average Return
+14.84%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 67.86% of your transactions generating a profit, with an average return of +14.84% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NBIX Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
0
1
7
7
10
Buy
51
40
44
29
27
Hold
4
4
5
4
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
55
45
56
40
43
In the current month, NBIX has received 37 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. NBIX average Analyst price target in the past 3 months is 182.79.
Each month's total comprises the sum of three months' worth of ratings.

NBIX Financial Forecast

NBIX Earnings Forecast

Next quarter’s earnings estimate for NBIX is $1.22 with a range of $0.78 to $1.98. The previous quarter’s EPS was $1.48. NBIX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year NBIX has Performed in-line its overall industry.
Next quarter’s earnings estimate for NBIX is $1.22 with a range of $0.78 to $1.98. The previous quarter’s EPS was $1.48. NBIX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year NBIX has Performed in-line its overall industry.

NBIX Sales Forecast

Next quarter’s sales forecast for NBIX is $771.22M with a range of $705.00M to $832.29M. The previous quarter’s sales results were $805.50M. NBIX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year NBIX has Performed in-line its overall industry.
Next quarter’s sales forecast for NBIX is $771.22M with a range of $705.00M to $832.29M. The previous quarter’s sales results were $805.50M. NBIX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year NBIX has Performed in-line its overall industry.

NBIX Stock Forecast FAQ

What is NBIX’s average 12-month price target, according to analysts?
Based on analyst ratings, Neurocrine’s 12-month average price target is 182.79.
    What is NBIX’s upside potential, based on the analysts’ average price target?
    Neurocrine has 37.18% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is NBIX a Buy, Sell or Hold?
          Neurocrine has a consensus rating of Strong Buy which is based on 21 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Neurocrine’s price target?
            The average price target for Neurocrine is 182.79. This is based on 23 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $242.00 ,the lowest forecast is $140.00. The average price target represents 37.18% Increase from the current price of $133.25.
              What do analysts say about Neurocrine?
              Neurocrine’s analyst rating consensus is a Strong Buy. This is based on the ratings of 23 Wall Streets Analysts.
                How can I buy shares of NBIX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.